Novavax, Inc. (NVAX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1158341,
    "name": "Novavax, Inc.",
    "stock_name": "Novavax, Inc.",
    "full_name": "Novavax, Inc.",
    "name_url": "stocks-analysis/novavax-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "6.86",
    "chg": 0.26,
    "chgp": "3.94%",
    "dir": 1,
    "prev_price": "6.60",
    "mcapval": "1,259.83",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US6700024010",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "4.17 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/novavax-inc-1158341-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Novavax, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novavax-changes-valuation-grade-from-fair-to-risky-amid-price-decline-3686243",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NovavaxInc_valuationdot_3686243.png",
        "date": "2025-11-10 15:52:40",
        "description": "Novavax, Inc. has recently adjusted its valuation, revealing a P/E ratio of 2 and a negative price-to-book value of -16.01. The company has faced significant stock declines, with an 18.95% drop over the past year and a 91.72% decrease over five years, contrasting with broader market gains."
      },
      {
        "title": "Novavax, Inc. Experiences Evaluation Revision Amid Mixed Market Signals and Performance Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novavax-inc-technical-trend-shifts-from-mildly-bullish-to-sideways-amid-stock-decline-3686156",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NovavaxInc_technicaldot_3686156.png",
        "date": "2025-11-10 15:23:43",
        "description": "Novavax, Inc. has recently adjusted its evaluation amid fluctuating market conditions, with its stock priced at $7.44. The company has faced notable volatility over the past year, underperforming the S&P 500. Technical indicators present mixed signals, reflecting the challenges in the competitive pharmaceuticals sector."
      },
      {
        "title": "Novavax, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novavax-inc-technical-trend-changes-from-bullish-to-mildly-bullish-amid-mixed-indicators-3648992",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NovavaxInc_technicaldot_3648992.png",
        "date": "2025-10-27 15:42:06",
        "description": "Novavax, Inc. has recently revised its evaluation amid current market dynamics, with its stock priced at $8.52. Despite a slight weekly gain, the company has faced a 14.11% decline over the past year and a significant 90.85% drop over the last five years, indicating ongoing challenges."
      },
      {
        "title": "Novavax Adjusts Valuation Metrics Amid Rising Sales and Profit Growth",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novavax-reports-90589-million-in-sales-and-63022-million-profit-amid-valuation-upgrade-3640196",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NovavaxInc_mojoScore_3640196.png",
        "date": "2025-10-23 15:42:18",
        "description": "Novavax, Inc. has recently adjusted its valuation metrics, moving from an expensive to a fair classification. The company reported a significant increase in net sales and profits, alongside a decrease in raw material costs. Its favorable P/E and EV to EBITDA ratios, along with high institutional holdings, indicate improved financial stability."
      },
      {
        "title": "Is Novavax, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-novavax-inc-overvalued-or-undervalued-3637221",
        "imagepath": "",
        "date": "2025-10-21 11:57:59",
        "description": "As of 17 October 2025, the valuation grade for Novavax, Inc. moved from expensive to fair. Based on the current metrics, the company appears to be undervalued. The P/E ratio stands at 2, significantly lower than the industry average, while the EV to EBITDA ratio is 1.38 and the PEG ratio is an exceptionally low 0.01, indicating potential for growth relative to its price.\n\nIn comparison with peers, Novavax's P/E ratio of 2.87 is notably lower than ADMA Biologics, Inc., which has a P/E of 18.56, highlighting a stark valuation discrepancy. Additionally, Novavax's EV to EBITDA ratio of 1.99 is also much lower than the industry average, reinforcing its undervaluation. Although return data is not available for a direct comparison with the S&P 500, the company's current valuation metrics suggest that it is positioned favorably in the market...."
      },
      {
        "title": "Novavax, Inc. Experiences Valuation Adjustment Amidst Unique Market Position and Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novavax-changes-valuation-grade-from-expensive-to-fair-amid-stock-decline-3640837",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NovavaxInc_valuationdot_3640837.png",
        "date": "2025-10-20 16:39:48",
        "description": "Novavax, Inc. has recently seen a valuation adjustment, with a notably low P/E ratio of 2.88 and an EV to EBITDA of 1.99. Despite these metrics, the company has faced significant negative returns over the past year and five years, contrasting sharply with broader market performance."
      },
      {
        "title": "Is Novavax, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-novavax-inc-overvalued-or-undervalued-3631629",
        "imagepath": "",
        "date": "2025-10-19 11:53:51",
        "description": "As of 17 October 2025, the valuation grade for Novavax, Inc. has moved from expensive to fair. Based on the current metrics, the company appears to be undervalued. Key ratios include a P/E ratio of 2, an EV to EBITDA of 1.38, and a PEG ratio of 0.01, all indicating a significant discount relative to typical valuations in the industry.\n\nIn comparison to peers, Novavax's P/E ratio of 2.88 is notably lower than ADMA Biologics, Inc., which has a P/E of 18.56, suggesting that Novavax is trading at a fraction of the value of its more highly valued counterparts. Additionally, while Novavax has faced substantial declines in stock performance, with a 5-year return of -92.43% compared to the S&P 500's 91.29%, this disparity further emphasizes its current undervaluation relative to broader market trends...."
      },
      {
        "title": "Novavax, Inc. Experiences Evaluation Revision Amid Mixed Market Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novavax-inc-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-stock-performance-gains-3601120",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NovavaxInc_technicaldot_3601120.png",
        "date": "2025-10-07 20:05:54",
        "description": "Novavax, Inc. has recently revised its evaluation amid ongoing market challenges, with its stock priced at $9.08. Despite short-term gains over the past week and month, the company has experienced significant long-term declines compared to the S&P 500, reflecting mixed technical indicators and a complex operational landscape."
      },
      {
        "title": "Is Novavax, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-novavax-inc-technically-bullish-or-bearish-3593422",
        "imagepath": "",
        "date": "2025-10-06 11:57:30",
        "description": "As of 3 October 2025, the technical trend for Novavax, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. Daily moving averages also confirm a bullish stance. However, the monthly KST is bearish, and Dow Theory shows a mildly bullish weekly but mildly bearish monthly outlook. \n\nIn terms of performance, Novavax has outperformed the S&P 500 over the past week and month, returning 10.64% and 27.84% respectively, while the S&P 500 returned 1.09% and 4.15%. However, the longer-term returns are significantly negative, with a 1-year return of -34.40% compared to the S&P 500's 17.82%. Overall, the current technical stance is bullish, with moderate strength driven by positive indicators in the short term...."
      }
    ],
    "total": 17,
    "sid": "1158341",
    "stock_news_url": "https://www.marketsmojo.com/news/novavax-inc-1158341"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Novavax, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape

2025-11-10 15:52:40

Novavax, Inc. has recently adjusted its valuation, revealing a P/E ratio of 2 and a negative price-to-book value of -16.01. The company has faced significant stock declines, with an 18.95% drop over the past year and a 91.72% decrease over five years, contrasting with broader market gains.

Novavax, Inc. Experiences Evaluation Revision Amid Mixed Market Signals and Performance Challenges

2025-11-10 15:23:43

Novavax, Inc. has recently adjusted its evaluation amid fluctuating market conditions, with its stock priced at $7.44. The company has faced notable volatility over the past year, underperforming the S&P 500. Technical indicators present mixed signals, reflecting the challenges in the competitive pharmaceuticals sector.

Novavax, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Challenges

2025-10-27 15:42:06

Novavax, Inc. has recently revised its evaluation amid current market dynamics, with its stock priced at $8.52. Despite a slight weekly gain, the company has faced a 14.11% decline over the past year and a significant 90.85% drop over the last five years, indicating ongoing challenges.

Novavax Adjusts Valuation Metrics Amid Rising Sales and Profit Growth

2025-10-23 15:42:18

Novavax, Inc. has recently adjusted its valuation metrics, moving from an expensive to a fair classification. The company reported a significant increase in net sales and profits, alongside a decrease in raw material costs. Its favorable P/E and EV to EBITDA ratios, along with high institutional holdings, indicate improved financial stability.

Is Novavax, Inc. overvalued or undervalued?

2025-10-21 11:57:59

As of 17 October 2025, the valuation grade for Novavax, Inc. moved from expensive to fair. Based on the current metrics, the company appears to be undervalued. The P/E ratio stands at 2, significantly lower than the industry average, while the EV to EBITDA ratio is 1.38 and the PEG ratio is an exceptionally low 0.01, indicating potential for growth relative to its price. In comparison with peers, Novavax's P/E ratio of 2.87 is notably lower than ADMA Biologics, Inc., which has a P/E of 18.56, highlighting a stark valuation discrepancy. Additionally, Novavax's EV to EBITDA ratio of 1.99 is also much lower than the industry average, reinforcing its undervaluation. Although return data is not available for a direct comparison with the S&P 500, the company's current valuation metrics suggest that it is positioned favorably in the market....

Novavax, Inc. Experiences Valuation Adjustment Amidst Unique Market Position and Challenges

2025-10-20 16:39:48

Novavax, Inc. has recently seen a valuation adjustment, with a notably low P/E ratio of 2.88 and an EV to EBITDA of 1.99. Despite these metrics, the company has faced significant negative returns over the past year and five years, contrasting sharply with broader market performance.

Is Novavax, Inc. overvalued or undervalued?

2025-10-19 11:53:51

As of 17 October 2025, the valuation grade for Novavax, Inc. has moved from expensive to fair. Based on the current metrics, the company appears to be undervalued. Key ratios include a P/E ratio of 2, an EV to EBITDA of 1.38, and a PEG ratio of 0.01, all indicating a significant discount relative to typical valuations in the industry. In comparison to peers, Novavax's P/E ratio of 2.88 is notably lower than ADMA Biologics, Inc., which has a P/E of 18.56, suggesting that Novavax is trading at a fraction of the value of its more highly valued counterparts. Additionally, while Novavax has faced substantial declines in stock performance, with a 5-year return of -92.43% compared to the S&P 500's 91.29%, this disparity further emphasizes its current undervaluation relative to broader market trends....

Novavax, Inc. Experiences Evaluation Revision Amid Mixed Market Performance Indicators

2025-10-07 20:05:54

Novavax, Inc. has recently revised its evaluation amid ongoing market challenges, with its stock priced at $9.08. Despite short-term gains over the past week and month, the company has experienced significant long-term declines compared to the S&P 500, reflecting mixed technical indicators and a complex operational landscape.

Is Novavax, Inc. technically bullish or bearish?

2025-10-06 11:57:30

As of 3 October 2025, the technical trend for Novavax, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. Daily moving averages also confirm a bullish stance. However, the monthly KST is bearish, and Dow Theory shows a mildly bullish weekly but mildly bearish monthly outlook. In terms of performance, Novavax has outperformed the S&P 500 over the past week and month, returning 10.64% and 27.84% respectively, while the S&P 500 returned 1.09% and 4.15%. However, the longer-term returns are significantly negative, with a 1-year return of -34.40% compared to the S&P 500's 17.82%. Overall, the current technical stance is bullish, with moderate strength driven by positive indicators in the short term....

View All News